Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-4444-8888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.72 billion
Profitability
Miscellaneous
Employees43,202
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a Semi-Annual dividend on Friday, August 9th. Shareholders of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S announced that its board has authorized a share buyback plan on Friday, February 2nd 2018, which allows the company to repurchase shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Friday, August, 9th. The company reported $0.61 earnings per share for the quarter, meeting analysts' consensus estimates of $0.61. The company earned $4.52 billion during the quarter, compared to analyst estimates of $4.41 billion. Novo Nordisk A/S had a return on equity of 75.16% and a net margin of 32.16%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What price target have analysts set for NVO?
15 Wall Street analysts have issued 1 year price targets for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $181.58 in the next year. This suggests a possible upside of 245.7% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
Media headlines about NVO stock have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Novo Nordisk A/S.
Are investors shorting Novo Nordisk A/S?
Novo Nordisk A/S saw a increase in short interest in September. As of September 30th, there was short interest totalling 6,490,000 shares, an increase of 12.1% from the August 30th total of 5,790,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is presently 4.1 days. Currently, 0.4% of the company's shares are short sold. View Novo Nordisk A/S's Current Options Chain.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Novo Nordisk A/S own?
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
- Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
- Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%), Scout Investments Inc. (0.01%), Cim LLC (0.01%), ST Germain D J Co. Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%) and Penbrook Management LLC (0.01%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including Arlington Partners LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Baldwin Brothers Inc. MA, Gradient Investments LLC, Whittier Trust Co. of Nevada Inc., Winslow Evans & Crocker Inc. and First Hawaiian Bank. View Insider Buying and Selling for Novo Nordisk A/S.
Which major investors are buying Novo Nordisk A/S stock?
NVO stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Ferguson Wellman Capital Management Inc., Intercontinental Wealth Advisors LLC, Mission Wealth Management LP, Atwater Malick LLC, Cim LLC, Pacer Advisors Inc. and Signaturefd LLC. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $52.52.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $124.37 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
